Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

AXL phosphosite mapping links FAK1 and YAP1 signaling to erlotinib resistance in EGFR-mutant lung cancer.

Cell reports - 28 Jul 2026

Creixell Marc, Taylor Scott D, Gerritsen Jacqueline, Jiang Mingxuan, Bae Song Yi, Augustin Teresa, Loui Michelle, Boixo Carmen, Minamino Saki, Gong Victoria, Creixell Pau, White Forest M, Meyer Aaron S

Abstract excerpt

Targeted therapies for receptor tyrosine kinases are effective but invariably limited by drug resistance. In EGFR-mutant lung cancer, AXL activation drives resistance to erlotinib by restoring cell survival and migration. To map these signaling mechanisms, we generated a panel of lung adenocarcinoma PC9 cell lines with phenylalanine substitutions at each intracellular AXL tyrosine residue. By integrating...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adaptor Proteins, Signal Transducing
Share to Axl Receptor Tyrosine Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Erlotinib Hydrochloride

Share to Focal Adhesion Kinase 1

Share to Phosphoproteins

Share to Receptor Protein-Tyrosine Kinases

Share to YAP-Signaling Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 42475177
DOI: 10.1016/j.celrep.2026.117717
PMCID: PMC13480988

Genes

AXL
EGFR
YAP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

AXL phosphosite mapping links FAK1 and YAP1 signaling to erlotinib resistance in EGFR-mutant lung cancer.PMID 42475177Read ↗

Dissecting signaling regulators driving AXL-mediated bypass resistance and associated phenotypes by phosphosite perturbationsSemantic proximity Read ↗

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.Semantic proximity Read ↗

Predictive data-driven modeling of C-terminal tyrosine function in the EGFR signaling networkSemantic proximity Read ↗

Tyrosine phosphoproteome profiling identifies cell-intrinsic signals limiting the efficacy of tyrosine kinase inhibitor therapiesSemantic proximity Read ↗

Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways.Semantic proximity Read ↗

Drug tolerance and persistence to EGFR inhibitor treatment are mediated by an ILK-SFK-YAP signaling axis in lung adenocarcinomaSemantic proximity Read ↗

Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer CellsSemantic proximity Read ↗

RAS-MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK Blockade.Semantic proximity Read ↗

MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma.Semantic proximity Read ↗

Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.Semantic proximity Read ↗

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML.Semantic proximity Read ↗

Characterizing tyrosine phosphorylation signaling in lung cancer using SH2 profiling.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.